Mylan to Acquire Aspen’s Thrombosis Business in the EU for ~ $758M

 Mylan to Acquire Aspen’s Thrombosis Business in the EU for ~ $758M

Mylan to Acquire Aspen’s Thrombosis Business in the EU for ~ $758M

Shots:

  • Mylan signed an agreement to acquire the related IP and commercialization rights of Aspen’s thrombosis business in the EU for $758.59M which include ~$311.08M as up front and ~$447.46 as deferred payment
  • The acquired portfolio includes Arixtra, Fraxiparine, Mono-Embolex, and Orgaran which complements and bolster Mylan’s complex injectables offering and presence in hospitals
  • The transaction is expected to be immediately accretive to Mylan upon closing and is anticipated to be accretive to VIATRIS upon the completion of Mylan’s combination with Upjohn, anticipated to be close in Q4’20

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Worldkings

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post